Interface stabilization via lithium bis(fluorosulfonyl)imide additive as a key for promoted performance of graphite‖LiCoO2 pouch cell under -20 ○C.

The effects of lithium bis(fluorosulfonyl)imide, Li[N(SO2F)2] (LiFSI), as an additive on the low-temperature performance of graphite‖LiCoO2 pouch cells are investigated. The cell, which includes 0.2M LiFSI salt additive in the 1M lithium hexafluorophosphate (LiPF6)-based conventional electrolyte, outperforms the one without additive under -20 °C and high charge cutoff voltage of 4.3 V, delivering higher discharge capacity and promoted rate performance and cycling stability with the reduced change in interfacial resistance. Surface analysis results on the cycled LiCoO2 cathodes and cycled graphite anodes extracted from the cells provide evidence that a LiFSI-induced improvement of high-voltage cycling stability at low temperature originates from the formation of a less resistive solid electrolyte interphase layer, which contains plenty of LiFSI-derived organic compounds mixed with inorganics that passivate and protect the surface of the cathode and anode from further electrolyte decomposition and promotes Li+ ion-transport kinetics despite the low temperature, inhibiting Li metal-plating at the anode. The results demonstrate the beneficial effects of the LiFSI additive on the performance of a lithium-ion battery for use in battery-powered electric vehicles and energy storage systems in cold climates and regions.

A New Pharmacokinetic Approach for a Better Understanding of the Relationship Between the Terminal Half-Life of Drug and Its Physiologically Based Pharmacokinetic Parameters.

The terminal half-life (T1/2) of a biphasic declining plasma concentration-time profile of a drug after intravenous administration is proportional to a ratio between its systemic clearance (CL) and volume of distribution at pseudo-distribution equilibrium (Vdß). Due to lack of understanding of Vdß, simply known as a proportionality constant between the amount of drug in the body and its plasma concentration during the terminal phase, the effects of various physiologically based pharmacokinetic parameters of drug on T1/2 could not have been evaluated. The objective of the current study is to offer a new theoretical ground, using the Taylor series expansion, for a better understanding of relationships among T1/2, CL, distributional clearance (CLd) and volumes of distribution in the tissue compartment (VT) and at steady state (Vdss) of drug in a 2-compartment model after intravenous administration. Similar CL and Vdss yet different T1/2 of drugs found in pharmacokinetic studies might be due to differences in CLd and VT of those drugs. In conclusion, the new equation (T1/2 ≈ 0.693 (Vdss/CL + VT/CLd) explicitly shows how the physiologically based pharmacokinetic parameters of drug could affect its T1/2 after intravenous administration.

Approaching the maximum capacity of nickel-rich LiNi0.8Co0.1Mn0.1O2 cathodes by charging to high-voltage in a non-flammable electrolyte of propylene carbonate and fluorinated linear carbonates.

We report a promising approach to achieve the maximum capacity (>230 mA h g-1) and high capacity retention (95% during 100 cycles) of a nickel-rich cathode of LiNi0.8Co0.1Mn0.1O2 (NCM811) by charging to 4.5 V in a non-flammable electrolyte of propylene carbonate and fluorinated linear carbonates. Our electrolyte permits the stabilization of the cathode-electrolyte interface and cathode structure at high-voltage, enabling stable and safe operation of the Ni-rich cathode for high-energy density and high-safety lithium-ion and lithium metal batteries.

Encapsulation and Functionalization of Nanoparticles in Crosslinked Resorcinarene Shells.

Two resorcinarene-derived tetrathiols with terminal alkene sidechains (tetraarylthiol cavitand 3 and tetrabenzylthiol cavitand 4) were determined to be efficient at extracting colloidal gold nanoparticles from aqueous solutions and stabilizing their dispersion in organic solvents. Treatment of these nanoparticle dispersions with the Grubbs olefin metathesis catalyst resulted in crosslinked resorcinarene shells that were highly resistant to alkanethiol-induced desorption at high temperatures. Nanoparticles in crosslinked shells of tetrabenzylthiol cavitand 4 were particularly robust, and could be precipitated and redispersed many times with minimal attrition. These shells could also withstand oxidative conditions and were amenable to synthetic modifications involving epoxidation and dihydroxylation.

Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.

BACKGROUND: ISIS 113715 is a 20-mer phosphorothioate antisense oligonucleotide (ASO) that is complementary to the protein tyrosine phosphatase 1B (PTP-1B) messenger RNA and subsequently reduces translation of the PTP-1B protein, a negative regulator of insulin receptor. ISIS 113715 is currently being studied in early phase II clinical studies to determine its ability to improve or restore insulin receptor sensitivity in patients with type 2 diabetes mellitus. Future work will investigate the combination of ISIS 113715 with antidiabetic compounds. METHODS: In vitro ultrafiltration human plasma protein binding displacement studies and a phase I clinical study were used to characterise the potential for pharmacokinetic interaction of ISIS 113715 and three marketed oral antidiabetic agents. ISIS 113715 was co-incubated with glipizide and rosiglitazone in whole human plasma and tested for increased free drug concentrations. In a phase I clinical study, 23 healthy volunteers received a single oral dose of an antidiabetic compound (either metformin, glipizide or rosiglitazone) both alone and together with subcutaneous ISIS 113715 200 mg in a sequential crossover design. A comparative pharmacokinetic analysis was performed to determine if there were any effects that resulted from coadministration of ISIS 113715 with these antidiabetic compounds. RESULTS: In vitro human plasma protein binding displacement studies showed only minor effects on rosiglitazone and no effect on glipizide when co-incubated with ISIS 113715. The results of the phase I clinical study further indicate that there were no measurable changes in glipizide (5 mg), metformin (500 mg) or rosiglitazone (2 mg) exposure parameters, maximum plasma concentration and the area under the concentration-time curve, or pharmacokinetic parameter, elimination half-life when coadministered with ISIS 113715. Furthermore, there was no effect of ISIS 113715, administered in combination with metformin, on the urinary excretion of metformin. Conversely, there were no observed alterations in ISIS 113715 pharmacokinetics when administered in combination with any of the oral antidiabetic compounds. CONCLUSION: These data provide evidence that ISIS 113715 exhibits no clinically relevant pharmacokinetic interactions on the disposition and clearance of the oral antidiabetic drugs. The results of these studies support further study of ISIS 113715 in combination with antidiabetic compounds.

Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors.

Phosphorylase is regulated by a number of small-molecular-weight effectors that bind to three sites on the enzyme. Recently, a fourth site referred to as the indole-inhibitor site has been identified. Synthetic compounds bind to the site and inhibit activity. However, the effects of these compounds in the presence of other endogenous effectors are unknown. We have determined the effects of four indole derivative glycogen phosphorylase inhibitors (GPI) on recombinant human liver glycogen phosphorylase a activity. The GPIs tested were all potent inhibitors. However, the endogenous inhibitors (glucose, ADP, ATP, fructose 1-phosphate, glucose 6-phosphate, UDP-glucose) and the activator (AMP) markedly reduced the inhibitory effect of GPIs. Consistent with these in vitro findings, the IC50 for the inhibition of glycogenolysis in cells and the liver drug concentration associated with glucose-lowering activity in diabetic ob/ob mice in vivo were also significantly higher than those determined in in vitro enzyme assays. The inhibitory effect of indole-site effectors is modulated by endogenous small-molecular-weight effectors of phosphorylase a activity. However, at higher concentrations (10-30 microM), the GPI effect was dominant and resulted in inhibition of phosphorylase a activity irrespective of the presence or absence of the other modulators of the enzyme.

Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase.

Diabetic dyslipidemia requires simultaneous treatment with hypoglycemic agents and lipid-modulating drugs. We recently described glycogen phosphorylase inhibitors that reduce glycogenolysis in cells and lower plasma glucose in ob/ob mice (J. Med. Chem., 41: 2934, 1998). In evaluating the series prototype, CP-320626, in dogs, up to 90% reduction in plasma cholesterol was noted after 2 week treatment. Cholesterol reductions were also noted in ob/ob mice and in rats. In HepG2 cells, CP-320626 acutely and dose-dependently inhibited cholesterolgenesis without affecting fatty acid synthesis. Inhibition occurred together with a dose-dependent increase in the cholesterol precursor, lanosterol, suggesting that cholesterolgenesis inhibition was due to lanosterol 14alpha-demethylase (CYP51) inhibition. In ob/ob mice, acute treatment with CP-320626 resulted in a decrease in hepatic cholesterolgenesis with concomitant lanosterol accumulation, further implicating CYP51 inhibition as the mechanism of cholesterol lowering in these animals. CP-320626 and analogs directly inhibited rhCYP51, and this inhibition was highly correlated with HepG2 cell cholesterolgenesis inhibition (R2 = 0.77). These observations indicate that CP-320626 inhibits cholesterolgenesis via direct inhibition of CYP51, and that this is the mechanism whereby CP-320626 lowers plasma cholesterol in experimental animals. Dual-action glycogenolysis and cholesterolgenesis inhibitors therefore have the potential to favorably affect both the hyperglycemia and the dyslipidemia of type 2 diabetes.